Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefapixant - Merck & Co

Drug Profile

Gefapixant - Merck & Co

Alternative Names: AF-219; Gefapixant citrate - Merck & Co; Gefzuris; LYFNUA; MK-7264; R 1646; RG-1646; RO-4926219

Latest Information Update: 21 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Merck & Co; Roche
  • Class Amines; Analgesics; Antiasthmatics; Antitussives; Benzene derivatives; Ethers; Pyrimidines; Sleep disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Cough
  • Discontinued Asthma; Interstitial cystitis; Musculoskeletal pain; Overactive bladder; Pain; Pelvic pain; Sleep apnoea syndrome

Most Recent Events

  • 20 Dec 2023 Merck & Co receives complete response letter from the US FDA for gefapixant in Cough
  • 31 Jul 2023 US FDA accepts Merck’s resubmission of the NDA for gefapixant in Cough in USA, following the company’s response to the complete response letter (Merck & Co pipeline, August 2023).
  • 21 Jul 2023 CHMP grants positive response for gefapixant in Cough
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top